factual
Five-year GBM survival rises from 5% to 13%
In the pivotal glioblastoma trial, the control group receiving radiation plus temozolomide had about 5 percent five-year survival, while adding Tumor Treating Fields raised five-year survival to about 13 percent, with survival curves separating at every point.
factualpending
Speaker
BillEvidence Quote
“we increased the five year survival from 5% to about 13%”
Created: 11/19/2026, 2:27:17 AM
Your notes
Loading notes...